CPA
CHRS icon

Capital Performance Advisors’s Coherus Oncology CHRS Stock Holding History

Capital Performance Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,117
Closed -$2.2K – 644
2024
Q3 		$2.2K Buy
+2,117
New +$2.9K ﹤0.01% 1516

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Capital Performance Advisors's CHRS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 2,117 shares — an estimated $2.2K sold.

Capital Performance Advisors first reported a position in CHRS in Q3 2024 and held it in 1 quarter. The position peaked at $2.2K in Q3 2024. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2,117 Coherus Oncology shares in Q4 2024, an estimated $2.2K.
  • Capital Performance Advisors first reported a position in Coherus Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Coherus Oncology position peaked at $2.2K in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.